CLOS
TXG icon

Compagnie Lombard Odier SCmA’s 10x Genomics TXG Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-98,783
Closed -$17.9M – 690
2021
Q1 		$17.9M Buy
+98,783
New +$17.1M 0.39% 53

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Compagnie Lombard Odier SCmA's TXG Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of 10x Genomics (TXG) in Q2 2021, closing a stake of 98,783 shares — an estimated $17.9M sold.

Compagnie Lombard Odier SCmA first reported a position in TXG in Q1 2021 and held it in 1 quarter. The position peaked at $17.9M in Q1 2021. 340 funds tracked by Wall St. Rank hold TXG as of Q2 2021.

  • Compagnie Lombard Odier SCmA reported no remaining 10x Genomics position as of Q2 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 98,783 10x Genomics shares in Q2 2021, an estimated $17.9M.
  • Compagnie Lombard Odier SCmA first reported a position in 10x Genomics in Q1 2021 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's 10x Genomics position peaked at $17.9M in Q1 2021.
  • 340 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.